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established last year to
accumulate baseline data on the
possible use of a tat-based
preventive and therapeutic HIV
vaccine in South Africa. These
projects were funded by the South
African AIDS Vaccine Initiative
[SAAVI).
It is hoped that phase I trials will be done first in Rome at
the ISS towards the end of 2001. If the vaccine is found to
be safe, phase 11 trials could begin soon after in South
Africa and Italy.
'Separate trial enrolment requirements are required to be
able to measure the preventative and therapeutic
outcomes of the vaccine, i.e. negative and positive
'It was decided to have two independent South African
sites because of the potential biological diversity of the
Soweto and Durban populations and probable virological
diversity; says Dr Vardas.
The South African sites will do both preventive and
therapeutic phase I1 trials, while the ISS will probably only
do the preventive phase II trial.
Currently in development is a new
collaborative application to be submitted to UNAIDS by the
Insituto Superiore di Sanita (ISS), the HIV/AIDS Vaccine
Division at the Perinatal HIV Research Unit (PHRU) in
Soweto and the Medical Research Council in Durban to
expand the existing collaboration and begin preparing
South African sites for phase 11 clinical testing of a tat-
based vaccine. The overall principal investigator is Or
Barbara Ensoli from the ISS, and the principal investigators
from the two South African sites are Dr Eftyhia Vardas,
Director of the HIV/AIDS Vaccine Division at the PHRU, and
Dr Mark Colvin of the MRC.
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HIV vaccines can be preventive (preventing infection in the
first place) or therapeutic (slowing down disease
progression in infected individuals by keeping viral load low
and CD4 counts high) or both. Most research so far has
been aimed at developing a safe, effective, preventive
vaccine for use in HIV-negative individuals to prevent
infection. However, there is also a focus on developing a
safe, cross-subtype reactive, therapeutic HIV vaccine that
can be used in people who are already infected.
COLLABORATION BETWEEN ITAlIAN
AND SOUTH AFRICAN SCIENTISTS
ON A TAT-BASED HIVVACCINE
Therapeutic vaccines are particularly important for South
Africa because there are already large numbers of people
living with HIV (the latest antenatal survey results estimate
that 4.7 million, or one in nine, South Africans are already
infected), who are unable to access expensive antiretroviral
treatments.
The urgent need to find an
effective HIV vaccine, and the
challenges this presents, have
forced scientists to investigate
various innovative approaches.
Most of the attempts made in the
last 15 years have focused on the
structural proteins of HIV aiming
at inducing immunity by blocking
virus entry. However, the failure of
this approach so far has led some
scientists to investigate strategies
aimed at controlling viral
replication and blocking disease
onset Recent approaches aimed at eliciting immunity
against the HIV regulatory gene products tat rev and nef
have shown good results. Tat vaccination appears capable
of controlling primary infection with highly pathogenic
SHIV (simian HIV) viruses providing evidence of cross-
protection in non-human primates. The tat gene is
relatively well conserved in its immunogenic regions
among most subtypes of HIV-1 and therefore may lead to
the development of a vaccine that could be used globally.
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individuals; says Or Vardas. 'Each phase I trial will also have
various trial arms to assess important safety and
immunogenicity aspects of the vaccine (including
adjuvants and antigen dosage):
DEVELOPING RURAL AND URBAN-BASED TRIAL
SITES - THE HIV!AIDS VACCINE DIVISION OF THE
PERINATAL HEALTH RESEARCH UNIT
The HIV/AIDS Vaccine Division of the Perinatal Health
Research Unit (PHRU) is developing both urban and rural
South African trial sites for phase I, II and III HIV vaccine
trials. The PHRU of the University of the Witwatersrand is
a unique research institution within the African region,
recognised internationally as a centre of excellence. The
unit is headed by Professor James Mclntyre and Or Glenda
Gray, while Or Eftyhia Vardas heads the vaccine division.
Funding for the development of vaccine trial sites is from
both the South African AIDS Vaccine Initiative and the
International AIDS Vaccine Initiative. The unit is in the
process of expanding, which involves the recruitment of a
laboratory manager, researcher and community workers.
The unit provides access to a number of potential cohorts
for expansion of urban-based phase III vaccine trials.
Current large-scale projects include four large sexually
transmitted disease (STD) projects and a study of
contraception and HIV risk in Orange Farm, Soweto. The
experience of cohort development and community
involvement in these sites makes them possible vaccine
trial sites.
Rural phase III site and cohorts are also being developed at
the Agincourt Health Centre and demographic site in
collaboration with Professor Steve Tollman and Or Kathy
Kahn from the Department of Community Health at the
University of the Witwatersrand. This demographic site was
established in 1991 by the Health Systems Development
Unit (HSDU) of the Department of Community Health,
University of the Witwatersrand, and Tintswalo Health
Service, and sited in a rural subdistrict of Bushbuckridge in
the Northern Province of South Africa. The Bushbuckridge
area lies approximately 500 km north-east of
Johannesburg in the central lowveld of the Northern
Province. The Drakensburg escarpment and commercial
forestry plantations bound the area to the west, the Kruger
National Park to the east, Hazyview to the south and the
Hoedspruit farming area to the north. The Agincourt site is
one of a series of international field demographic
surveillance system field sites with continuous
demographic evaluation of populations and their health in
developing countries.
Since 1992, the programme has maintained a demographic
and health surveillance site encompassing a subdistrict of
approximately 63 000 people living in 20 villages. Research
has included projects on the impact of labour migration on
men's contraceptive use and sexual risk behaviour;
circulatory disease and interpersonal violence among
adults; kwashiorkor and respiratory syncytial virus in
children under 5; the links between refugee health and
legal/employment status; and evaluation of service and
social interventions that address mental health, adolescent
health, STD/HIV transmission and TB. The subdistrict is also
a national pilot site for the strengthening of HIV{TB district
services.
The site is ideally situated to be part of a phase II and III HIV
vaccine-testing site because of the well-described
demographic profile of these communities and the well-
mapped geography of the region. Initially studies will be
done to determine the incidence and prevalence of HIV
infection, the willingness of the community to participate
in HIV vaccine trials and the development of community
education on vaccines. Systems for HIV rapid testing will be
set up at the rural site to strengthen disease surveillance
and diagnostic services in the area.
WOULD SOWETO RESIDENTS PARTICIPATE
IN AN HIV VACCINE TRIAL?
A preliminary study to assess the attitudes towards HIV
vaccine research in Soweto residents has also been done by
the PHRU and the University of Chicago. Volunteers from
clinic waiting areas and shopping centres in Soweto were
recruited.
Of the 57 Soweto residents interviewed, 68% indicated
that they would 'definitely consider volunteering' for an
HIV vaccine trial, 16% were undecided and 16% said they
would not consider ever being in an HIV vaccine trial.
Overall, the majority of respondents admitted that they
would prefer to participate in a trial that offered them
access to free HIV tests (67%), care for STDs (75%). and
access to risk-reduction counselling (79%) and condoms
(67%).
Seventy per cent of respondents thought that researcher
sponsors should be responsible for providing general
medical care to vaccine trial participants, 39% thought
that research sponsors were responsible for providing
antiretroviral therapy, 46% thought this was not an
obligation, and 14% answered 'Don't know:
A new project will expand this pilot study. The aim is to
accumulate relevant baseline community demographic
data, community attitudes to vaccines and HIV vaccine
research, as well as establishing HIV prevalence and
incidence figures in both the urban (Soweto) and rural
(Agincourt) HIV vaccine test sites. This comprehensive
large-scale study will start towards the end of June.
